Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases

Sujata Maurya, Rashi Srivastava, Saniya Arfin, Susan Hawthorne, Niraj Kumar Jha, Kirti Agrawal, Sibi Raj, Brijesh Rathi, Arun Kumar, Riya Raj, Sharad Agrawal, Ana Cláudia Paiva-Santos, Asrar Ahmad Malik, Kamal Dua, Rakesh Rana, Shreesh Ojha, Saurabh Kumar Jha, Ankur Sharma, Dhruv Kumar, Sally A El-ZahabyAmka Nagar

Research output: Contribution to journalReview articlepeer-review

4 Downloads (Pure)

Abstract

Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.
Original languageEnglish
Pages (from-to)2245-2264
Number of pages20
JournalNANOMEDICINE
Volume17
Issue number30
Early online date31 Jan 2023
DOIs
Publication statusPublished (in print/issue) - 28 Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.

Keywords

  • Review
  • biopharmacokinetic
  • cystic fibrosis
  • lung diseases
  • nanocarriers
  • nanomedicines
  • therapeutics

Fingerprint

Dive into the research topics of 'Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases'. Together they form a unique fingerprint.

Cite this